Small Pharma’s Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business
Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc.
Harvard’s New Psychedelics Research Program Backed By Former Tesla Director’s $16M Donation
Harvard University will create a Study of Psychedelics in Society and Culture backed by a $16 million gift from a former Tesla (NASDAQ: TSLA) employee, recalling
Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement
Short-acting psychedelics biotech Small Pharma Inc.
Bionomics Meets The FDA: Lead Drug Candidate For Social Anxiety Heads To Phase 3
Biopharma company Bionomics Ltd.
Lucy Scientific’s Fiscal Year: Operating Expenses Rise As Accumulated Deficit Hits Over $44M
Psychedelics company Lucy Scientific Discovery Inc. (NASDAQ: LSDI) reported its full-year results for the period ended June 30, 2023. Numbers show:
Total cash held of $1.67 million, vs. $53,379 held in June 30, 2022.
Johnson & Johnson’s Q3 2023: $21.3B Rise In Sales, ‘Sharpened Focus’ On Innovation & Biotech Solutions
Healthcare company Johnson & Johnson (J&J) (NYSE: JNJ) shared its financial outcomes for the third quarter of 2023, reflecting:
Psyched: FDA Warning, DEA’s Telehealth Extension, CA Gov’s Veto, Congress On Kratom, M&As & More
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution
U.K.’s Prof. David Nutt Ranked World’s Top Psychopharmacologist: More On His Contributions & Advocacy
Professor David Nutt, a cognitive sciences, addiction, cannabis and psychedelics researcher, has been ranked the #1 psychopharmacologist by ScholarGPS, a California-based American company owned and operated by Meta Analytics LLC.
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates
Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc.
Psychedelic-Based Drugs Biotech Company Begins Trading On UK’s AQSE Growth Market
Novel psychedelic-based drugs biotech Mydecine Innovations Group, Inc. (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA) completed its admission to Access segment of the UK’s stock market, AQSE Growth Market. Trading started on Tuesday under ticker MYIG.